Navigation Links
Two Drugs Better Than One for High Blood Pressure
Date:3/31/2008

Pairing ACE inhibitor with calcium channel blocker beat pairing it with diuretic; Celebrex study finds dose related to heart risk

MONDAY, March 31 (HealthDay News) -- A large trial shows that combining an ACE inhibitor with a calcium channel blocker in individuals with high blood pressure who are at high risk for cardiovascular complications resulted in a 20 percent reduction in the risks of death, heart attack, stroke and other cardiovascular troubles.

The ACE inhibitor and calcium channel blocker were combined in a single pill. Patients receiving this treatment were compared to patients who received an ACE inhibitor combined with a diuretic.

The authors of the study, which was halted early because the results were so strong, presented the interim results during a news conference Monday at the American College of Cardiology annual meeting, in Chicago. Their hope is that the findings will change current practice guidelines.

"This strategy challenges our current guidelines in two important ways. First, the idea that monotherapy [starting out on a single pill] should be the rule of stay is now challenged and, second, guidelines have recommended that we use a diuretic, and we show that an ACE inhibitor and calcium channel blocker are superior," said study author Dr. Kenneth Jamerson, a professor of internal medicine at the University of Michigan Medical School.

The trial randomized more than 10,000 individuals, two-thirds of whom came into the study with inadequately controlled blood pressure. The use of the combination tablet as the first line of treatment more than doubled the number of patients who managed to get their hypertension under control, the study authors said in a statement. Novartis, which is one of the companies offering the two-drug combination tablet, funded the study.

A second study presented at the news conference refines the safety profile for Celebrex, the only cox-2 painkiller still sold in the United States and the most widely prescribed in its class around the world. The drug carries a black-box warning about an increase in cardiovascular risks for users.

The authors reviewed existing data from several trials and combined them in one comprehensive analysis, finding a clear relationship between dose and cardiovascular risk.

Individuals taking 400 milligrams of Celebrex twice a day had a threefold increase in cardiovascular risk. Those taking 200 milligrams twice a day had double the risk.

In addition, patients who had a low risk when they started taking the painkiller continued to show a low risk of having a Celebrex-induced cardiovascular problem later, while those starting out at high risk were more likely to suffer cardiovascular consequences while taking Celebrex, especially at the higher doses. The analysis was published simultaneously Monday in the online edition of Circulation.

"Perhaps this will give us a little bit of comfort when we prescribe Celebrex to patients who are at very, very low cardiovascular risk, but it will perhaps make us considerably more cautious when prescribing to those at high risk," said study author Dr. Scott Solomon, director of noninvasive cardiology at Brigham and Women's Hospital in Boston. "The doses we were able to test were considerably higher than typical arthritis patients are taking."

A third study from the news conference brought more good news for Crestor (rosuvastatin). In a study funded by drug maker AstraZeneca, treatment with this statin for two years lowered average LDL ("bad") cholesterol levels and increased HDL ("good") cholesterol levels, resulting in regression of coronary atherosclerosis. Earlier Monday, AstraZeneca announced that it had halted another trial of Crestor because of "unequivocal" evidence that it was better than a placebo.

"Ninety-seven percent of participants were either stable or had regression," said Dr. Christie M. Ballantyne, of the section of atherosclerosis and vascular medicine in the department of medicine at Baylor College of Medicine and the Methodist DeBakey Heart & Vascular Center. Ballantyne added that the trial lends credence to the strategy of lowering LDL levels.

More information

Visit the American Heart Association for more on high blood pressure.



SOURCES: March 31, 2008, teleconference with Kenneth Jamerson, M.D., professor, internal medicine, University of Michigan Medical School, Ann Arbor; Scott D. Solomon, M.D., director, noninvasive cardiology, Brigham and Women's Hospital, Boston; Christie M. Ballantyne, M.D., section of atherosclerosis and vascular medicine, department of medicine, Baylor College of Medicine, and the Methodist DeBakey Heart & Vascular Center; March 31, 2008, presentations, American College of Cardiology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Can cancer drugs combine forces?
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. RA Drugs Linked to Slight Skin Cancer Risk
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
11. 2 drugs equally effective for heart patients undergoing angioplasty, Mayo study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Two Drugs Better Than One for High Blood Pressure
(Date:9/22/2017)... ... , ... "Success Files," a short- and long-form documentary style ... disease estimated to affect the lives of more than 5 million Americans living ... leading voice in the fight for cure and research into the disease, its ...
(Date:9/22/2017)... ... 2017 , ... Egg freezing and embryo freezing are both ... slight statistical advantage for live births, frozen eggs offer many advantages, depending on ... medical treatment or who are concerned about the decline of their fertility as ...
(Date:9/21/2017)... ... 2017 , ... SABRE is raising awareness about personal safety with a Chicago ... November. , The Chicago, Illinois, based self-defense brand has been waiting for an opportunity ... of taking their personal safety into their own hands. , The ads focus on ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... Bill Howe ... to its customers, and give back to the community. For over 37 years, they ... most successful companies serving plumbing in San Diego. They were chosen as ...
(Date:9/21/2017)... ... September 21, 2017 , ... Japanese Zen artist couple, ... Revolution” on 6th, 7th and 8th October at Miranda Kuo Gallery on Lower East ... pieces, such as Zen Kodo mat. Wanderlust , one of the largest US ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
(Date:8/29/2017)... 29, 2017 ivWatch, LLC, the leading provider of continuous ... it has been awarded an Innovative Technology contract from Vizient, Inc., ... ... aid in the early detection of peripheral IV infiltration and extravasation ... The Innovative Technology contract was awarded ...
Breaking Medicine Technology: